ABSTRACT
Results: In most cases, neoplastic B cells were not detected by flow cytometry. Overall, cases showed a predominance of CD4+ T cells, which in some cases was marked. Significant coexpression of CD57 was seen on CD4+ T cells where this marker was analyzed, which correlated with PD-1 expression. Two cases also showed a profound systemic B-cell lymphopenia, which was associated in one case with hypogammaglobulinemia.

Conclusions: Overall, our work challenges previous findings that cases of THRLBCL are rich in CD8+ T cells and highlights parallels between THRLBCL and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Also, an association of THRLBCL with systemic B-cell lymphopenia has not been previously reported but may represent an underrecognized manifestation.
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a poorly understood subtype of large B-cell lymphoma characterized by scattered rare large, atypical B cells in a background consisting of T cells and histiocytes, accompanied by few if any small B cells or residual follicular dendritic cell meshworks. 1 The clinical presentation of THRLBCL is similar to other large B-cell lymphomas, although there appears to be a significant male predominance, and it often presents at a higher stage than other types of diffuse large B-cell lymphoma (DLBCL). However, when matched stage for stage, it appears to have a similar outcome to usual DLBCL. 2 There is mounting evidence for a biological relationship between at least a subset of THRLBCL and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Some cases show a mixture of the two histologies, and THRLBCL has been hypothesized to represent a form of disease progression from NLPHL. [3] [4] [5] [6] Most cases of transformation of NLPHL progress to "usual" DLBCL (sheets of large B cells), although a notable minority may show a T-cell/histiocyte-rich pattern. 7, 8 One interesting report documents the occurrence of clonal THRLBCL in axillary lymph nodes and concurrent NLPHL in inguinal lymph nodes in a man with a longstanding history of inguinal lymphadenopathy with recent progressive axillary lymphadenopathy and B symptoms, supporting that such cases may progress in this fashion. 9 Although cases of NLPHL with THRLBCL-like areas present at higher stage than most cases of NLPHL, they have a superior outcome to de novo cases of THRLBCL. 10 The 2016 World Health Organization (WHO) classification asserts that any nodular architecture excludes the diagnosis of THRLBCL.
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The characteristics of the accompanying reactive infiltrate in THRLBCL have not been extensively studied. Early studies reported a moderate predominance of CD4+ T cells, 12, 13 and subsequent studies have emphasized a predominance of CD8+, TIA-1+ T cells, 10,14-17 although most reports have not addressed the issue consistently or with rigorously quantitative data. However, in early studies where the CD4/CD8 ratio was reported, even in cases with CD8+ predominance, the ratio was not more than 1:3, and a significant minority had an excess of CD4+ T cells. 17 The sole study to report numerical densities of CD4+ and CD8+ T cells reported a higher median density of CD4+ than CD8+ T cells in THRLBCL, despite commenting that "it is well known that reactive T cells in THRLBCL mainly correspond to CD8+ T cells with only few CD4+ T cells." 18 Finally, a recent study using flow cytometry demonstrated a CD4/CD8 ratio of greater than 1 in most cases and furthermore noted that the highest ratios of all the samples tested (which included classical Hodgkin lymphoma, NLPHL, and reactive lymph nodes) were in cases of THRLBCL. 19 This unresolved issue is of significant importance because the predominance of CD8+ T cells has become a diagnostic feature for some pathologists in the differential diagnosis of THRLBCL and closely related entities, including NLPHL.
The pathways leading to the predominance of T cells and histiocytes in these cases are essentially unknown, although one report described overexpression of interleukin 4 by tumor cells by immunohistochemistry, which was not seen in usual cases of DLBCL or in reactive conditions. 20 This finding has not been followed up to our knowledge. Gene expression profiling studies (most of which focused on other entities but including a few cases of THRLBCL) reported overexpression of genes related to macrophage and T-cell function, as would be expected. 17, [21] [22] [23] Genes relevant to antiviral responses were highlighted in one study, and furthermore, a marked upregulation of PD-1 was noted. This was confirmed by immunohistochemistry in all 13 of their cases, without expression of the T follicular helper cell marker CXCL13 or the T regulatory cell marker FOXP3; however, CD4 and CD8 were not evaluated. 23 We have also observed extensive PD-1 reactivity in the background infiltrate of some cases of THRLBCL, including on CD4+ T cells. 24 One THRLBCL study specifically focused on the marked overexpression (compared with NLPHL) of VSIG4 and CCL8, as well as other genes predicted to lead to a tolerogenic host environment. 17 A subsequent single-cell expression profiling study of the tumor cells reported that cases of NLPHL, THRLBCL-like NLPHL, and THRLBCL did not segregate by histologic type in either unsupervised or supervised analyses, further underscoring the biological relationship between these entities. 18 Overall, however, the biological and genetic underpinnings of this disease remain largely unknown, owing to its rarity and also to the rarity of neoplastic cells in tissue samples. Like many lymphomas, an inconsistent and heterogeneous set of associations with immune phenomena also has been reported, including hypogammaglobulinemia, 4 a case with hypogammaglobulinemia and Epstein-Barr virus (EBV)-related hemophagocytic syndrome, 25 erythema nodosum, 26 pure RBC aplasia, 27 and autoimmune hemolytic anemia. 28 Due to conflicting reports about the CD4/CD8 ratio in THRLBCL and our experience that CD8-predominant cases appeared rare, we undertook this study to further examine the issue. We also investigated the clinical context of these cases to determine whether additional immune-related associations could be identified.
Materials and Methods
Case Selection
The case records of four major institutions, between 2001 and 2016, were retrospectively searched for cases of THRLBCL or cases with a THRLBCL-like component in which multiparameter flow cytometry was performed as part of the initial diagnostic clinical workup. Medical record data of all patients were reviewed. This study has been approved by Stanford University's institutional review board.
Morphologic and Immunohistochemical Stains
Cases were diagnosed according to the 2016 WHO criteria. 1 Images were taken on a BX52 microscope (Olympus, Waltham, MA) using a SPOT Insight camera and SPOT 5.0 imaging software (Diagnostic Instruments, Sterling Heights, MI). Immunohistochemical stains were performed using antibodies at all institutions as a part of routine clinical practice.
Flow Cytometry
Flow cytometry was performed on tissues processed as previously described. 29 Cells were washed in phosphate-buffered saline and treated with ammonium chloride RBC lysis buffer (Pharmlyse; BD Biosciences, San
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Jose, CA) before labeling with antibodies. Cytoplasmic or nuclear staining antibodies required an additional step of permeabilization during antibody labeling. Monoclonal antibodies against κ, λ, CD19, CD20, CD45, CD38, CD4, CD8, and CD3 were used in all cases. In subsets of cases, antibodies against CD56, CD57, and CD16 were also used. CANTO II or CALIBUR Flow Cytometers (BD Biosciences) were used and data analyzed using FACSDiva (BD Biosciences), FCS Express (BD Biosciences), and/or Flowjo (Flowjo, Ashland, OR).
Results
Clinical Cohort
A summary of the clinical data is given in ❚Table 1❚. Fifteen cases presenting as pure THRLBCL were identified. We also included for comparison three cases that presented with a mixture of THRLBCL-like and NLPHL-like patterns, which according to the 2016 WHO classification would be considered NLPHL. The THRLBCL-like areas in these cases were diffuse without a significant component of small B cells, in distinction from the T-cell-rich nodular pattern (pattern D) of NLPHL. 30 Also included was one case of THRLBCL in a patient with a history of NLPHL.
In keeping with the published literature on THRLBCL, the cases we identified were predominantly in males (male/ female ratio of 4.0). The mean age at diagnosis was 45.5 years. Six patients for whom staging information was available all had high-stage disease (stages III and IV).
Multiparametric Flow Cytometry Findings
A summary of the flow cytometric findings is presented in ❚Table 2❚. In all cases, the CD4/CD8 ratio was greater than 1.5, and 11 (73.3%) of the 15 cases with pure THRLBCL had ratios of at least 5.0. The mean CD4/ CD8 ratio in these 15 cases was 14.2. Interestingly, we also identified two cases with a THRLBCL-like pattern in which the neoplastic B cells were EBV+; these cases were relatively richer in CD8+ T cells (with ratios of 0.98 and 2.6). Although we mention these two cases, they were excluded, as, according to the 2016 WHO classification, they should be considered EBV+ DLBCL not otherwise specified. Such EBV+ cases might be expected to harbor EBV-specific cytotoxic T cells, which might explain the increased numbers of CD8+ T cells, although this was not further investigated. CD4+ T cells in most of the cases tested showed a marked partial coexpression of CD57, which was associated with PD-1 expression by immunohistochemistry ❚Image 1❚. Because these cases were assembled from multiple institutions retrospectively, flow immunophenotyping for CD57 and immunohistochemistry for PD-1 were only available in a subset. A few cases showed additional atypical T-cell antigen expression, including partial CD7 loss (cases 2 and 4) and increased CD4/CD8 double-positive T cells (case 16). Cases with a component of NLPHL and the case representing THRLBCL as progression from NLPHL had a similar T-cell background to those pure THRLBCL cases with the highest CD4/CD8 ratios, with coexpression of CD57 and PD-1.
THRLBCL With Peripheral B-Cell Lymphopenia
One of the cases in this series (case 5) was discovered incidentally. A biopsy specimen of a colon polyp obtained at a routine screening colonoscopy revealed an atypical lymphoid infiltrate containing EBV+ large B and T lymphocytes. The subsequent workup revealed hepatic and splenic masses as well as widespread lymphadenopathy, and the patient endorsed a 1-month history of night sweats and modest weight loss. Peripheral blood flow cytometry showed marked B lymphopenia (absolute count, 3.6 cells/µL; normal range, 100-500/ µL) as well as hypogammaglobulinemia (immunoglobulin G [IgG], 141 mg/dL; normal range, 613-1,295 mg/dL). Before the diagnostic excisional lymph node biopsy specimen demonstrating THRLBCL (EBV-), hereditary immunodeficiency syndromes and infectious disease were favored in the clinical differential diagnoses. Flow findings in the excisional lymph node biopsy specimen closely reflected those in the peripheral blood, showing a marked decrease in B cells and large numbers of CD4+CD57+ T cells ❚Image 2❚, which were positive for PD-1 and CXCL13 by immunohistochemistry (not shown). The patient was treated with six cycles of dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DAR-EPOCH) chemotherapy, achieving a complete response. A follow-up positron emission tomography/ computed tomography scan showed a new fluorodeoxyglucose avid subpectoral lymph node, which was excised and interpreted as atypical, favoring NLPHL.
Of the five additional patients for whom CBCs were available from the time of diagnosis, three were lymphopenic (absolute lymphocyte counts of 0.5, 0.6, and 0.9 × 10 3 /µL); B-cell counts were not available. One other patient (case 2) had no detectable circulating B cells at presentation, despite a normal lymphocyte count and elevated IgG levels.
Discussion
The findings presented in this study have several implications. First, they challenge the oft-repeated notion that the nonneoplastic background of THRLBCL is rich in CD8+ T cells and suggest that this criterion should not be a major consideration when making this diagnosis in practice. But while the CD4/CD8 ratio in our series exceeded 1.5 in all cases, there was significant variation, and cases 14 shows a clear predominance of cases with excess CD8+ cells, subsequent studies that appear to support this conclusion did not address it directly. More quantitative recent studies seem to support our findings, suggesting that many cases have more CD4+ than CD8+ T cells, although CD8+ T-cell-predominant cases clearly occur. 19 The differences at the biological level between cases with markedly skewed CD4/CD8 ratios in either direction remain a matter of speculation. We feel that cases with very high CD4/CD8 ratios likely reflect biology that dysregulates T follicular helper (T FH ) cells and germinal center formation; in other words, this pattern is an exaggerated version of the immunoarchitectural disruption that occurs in NLPHL (just as germinal center-type DLBCL is, in a sense, an exaggerated version of follicular lymphoma). It is likely that cases rich in CD8+ T cells are unrelated to NLPHL and represent a ❚Image 1❚ (cont) E, CD4 highlights a similar proportion of small lymphocytes as PD-1. F, CD8 labels scattered cells.
completely distinct pathogenesis, but this remains to be established. The fact that cases of "pure THRLBCL" with the most dramatically skewed CD4/CD8 ratios also aligned with cases that showed a mixture of this pattern with NLPHL or occurred after a diagnosis of NLPHL provides additional evidence for the relationship between these two entities. This is underscored by case 5, in which the recurrence resembled NLPHL, despite the diagnostic material being unequivocally THRLBCL. This finding calls into question the prevailing criterion that a diagnosis of THRLBCL is excluded by the presence of an NLPHL-like nodule, especially as the mixture of these two patterns occurs more frequently in patients with high-stage disease. Our current practice is to diagnose such cases as "NLPHL with THRLBCL-like areas" and then to identify that this remains an area of uncertainty, but current evidence suggests that such cases behave more aggressively than pure NLPHL.
The expression of CD57 and PD-1 on the CD4+ T cells in those cases with high CD4/CD8 T-cell ratios is intriguing. Both of these molecules are considered markers of the T FH subset, and expansions of these cells appear to occur in the development of NLPHL, resulting in disrupted nodules with CD4+CD57+ T cells forming rosettes around the malignant B cells, 10 although some have suggested a distinction between rosetting T cells and intranodular clusters of T cells, with only the latter showing considerable expression of the more specific marker CXCL13. 31 However, in CD8+ T cells, PD-1 is considered a marker of "exhaustion" in the setting of chronic viral infection, 32 and CD57 also is expressed on large granular (generally CD8+) T cells and natural killer cells. In summary, neither PD-1 nor CD57 alone are entirely specific markers for T-cell subset lineage.
The best-known physiologic role of the T FH subset is the production of CXCL13, a B-cell chemoattractant. This process is necessary for the recruitment of B cells into follicles and ultimately germinal centers. The finding that these cells are greatly expanded in NLPHL and even more so in similar cases of THRLBCL (to the point of making up a substantial percentage of circulating T cells) is hard to reconcile with the depletion of small B cells that occurs in lymph nodes affected by the latter entity (or systemically as seen in the two cases with B-cell lymphopenia in this series), although it could be an ineffective compensatory response.
Lymphopenia in several of our cases, or specifically profound B-cell lymphopenia, may confound the initial diagnostic process, giving the appearance of immunodeficiency. To our knowledge, this association has not been widely recognized previously, although a few reports of THRLBCL in association with hypogammaglobulinemia have been reported. 4, 25 Our series does not permit an estimate of how common this phenomenon might be. Due to its retrospective nature, only limited clinical information was available for many cases, and peripheral blood T-and B-cell subsets are not routinely evaluated during a typical lymphoma workup. Of course, once chemotherapy is initiated, lymphopenia is an expected outcome. What biological process leads to this lymphopenia prior to medical intervention is unclear and will require further study, but presumably it is somehow related to the process of B-cell depletion that occurs in involved lymph nodes. It is also unclear whether this finding has any clinical significance; one might speculate that it could be associated with high stage (similar to other systemic manifestations of neoplasia), but additional studies would be necessary to determine this. Aside from being aware of this association, which might lead one away from the diagnosis of lymphoma, whether actually testing patients for this finding is valuable will await such studies.
In addition to the small number of patients, this study has several limitations. Clinical and laboratory data are limited for many of the cases because of a reliance on the use of archived data and materials from consultation material. It is possible that these cases do not reflect the normal spectrum of THRLBCL for the same reason, although its rarity implies that many if not most diagnoses are made most appropriately after expert consultation.
Nonetheless, our findings here offer clear, quantitative evidence that THRLBCLs are typically rich in CD4+ T cells, which in many cases show a T FH -like immunophenotype. We also present cases of THRLBCL with a profound systemic B-cell lymphopenia, a systemic finding that may be an underrecognized occurrence.
